Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for
the treatment of social impairment in youth with Non-Verbal Learning Disorder,
High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will
be males and females ages 8-18.
This study consists of up to 6 visits to Massachusetts General Hospital.